Key facts
- Lightcast (Biotechnology)’s last known valuation is $138.9M (Jul 2024).
- It has raised $140.9M; the latest was Later Stage VC ($27.0M) in Apr 2026.
- Notable investors include ARCH Venture Partners, M Ventures, Illumina Ventures, Perscitus, Longwall Ventures — 9 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 9 names
- ·Watchlist + deal alerts for Lightcast (Biotechnology)
- ·The full record, as it builds
Funding rounds
No funding rounds for Lightcast (Biotechnology) are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Lightcast (Biotechnology)
Developer of a microfluidic technology designed to manipulate individual microscopic droplets encapsulating cells with flexibility. The company's technology helps to detect and automatically count the number of cells in each droplet, and the droplets can be organized to perform parallel, sequential assays with multiple readouts, enabling healthcare clients to perform workflows and allow specific droplets of interest to be dispensed while maintaining viable cells in the dispensed droplets.
- Sector
- Healthcare
- HQ
- Cambridge, United Kingdom
- Founded
- 2019
- Employees
- 100
- Website
- lightcast.bio/
- Ownership
- Privately Held (backing)
Lightcast (Biotechnology) doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Lightcast (Biotechnology) shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Lightcast (Biotechnology) in its N-PORT filings yet. We sweep new filings monthly.